INTRODUCTION

Among individuals with heart failure with preserved ejection fraction (HFpEF), the proportion of those older than 65 years is more than 60%.\(^1\)\(^-\)\(^3\) Besides prevalent cardiac and noncardiac morbidities, age-related alterations in cardiac and arterial structure and function might also explain the HFpEF epidemic in the elderly.\(^4\)\(^-\)\(^5\) For example, among community residents without cardiovascular disease who had echocardiographic examination were included. Age-related alterations in cardiac and arterial structure and function were compared by sex, and interplay between age and sex was analyzed according to achieved systolic blood pressure (SBP) level. The mean age of the cohort was 66.5 years, and women accounted for 62% (n = 602) of the cohort (n = 971). Compared to men, women had worse left ventricular (LV) diastolic function and greater LV and arterial stiffness. After adjusting for covariates, the magnitude of the associations between age with septal E/e' ratio, septal S' velocity, effective arterial elastance (Ea) and LV end-diastolic elastance (Eed) were greater in women. Sex differences in the magnitude of association between age with these four indices varied according to achieved SBP level. When achieved SBP <130 mm Hg, the magnitude of the associations between age with septal E/e' ratio, septal S' velocity, Ea and Eed did not differ by sex. Since age and sex are non-modifiable, achieving SBP target, especially at a lower level, might be beneficial to attenuate sex differences in age-related alterations in cardiac and arterial structure and function.
and hypertension, advancing age is associated with increases in left ventricular (LV) and arterial stiffness and decrease in LV relaxation,\(^6\) which are purported to contribute to the pathogenesis of HFpEF.\(^9\)–\(^11\)

Women, especially elderly women, are more likely than men to have HFpEF.\(^12\)–\(^13\) Sex differences in the age-related cardiac and arterial alterations might partly explain the difference. For example, Redfield and colleagues\(^7\) reported that LV end-systolic elastance (Ees), an index of LV stiffness, increased more steeply with age in women than in men. Among Japanese populations without CVD and hypertension, peak early diastolic mitral annular velocity (e’), an index of LV relaxation, deteriorated more greatly in women than in men in individuals older than 70 years.\(^6\) One recent study from Chinese hypertensive individuals without CVD showed that the magnitude of the association between blood pressure (BP) with E/e’ ratio, an index of LV filling pressure, and effective arterial elastance (Ea), an index of arterial stiffness, were greater in women than in men.\(^14\)

Blood pressure elevation is associated with increase in LV and arterial stiffness and decrease in LV relaxation. Reduction of systolic BP (SBP) is beneficial for the improvement of LV relaxation which is purported to contribute to the pathogenesis of HFpEF.\(^6\)–\(^8\) Among Japanese populations without CVD and hypertension, advancing age is associated with increases in LV and arterial stiffness, were greater in women than in men.\(^6\)–\(^8\),\(^14\)–\(^17\) data from Chinese community populations and analyses of interplay between age and sex in hypertensive individuals without CVD are limited. According to the China guideline’s recommendation,\(^20\) two BP measurements were performed with 1-minute interval with the arm positioned at the heart level using Omron HEM-7051 device (Omron HealthCare). Healthcare staff was attended during BP measurements. The average value of two BP readings was used. If the first two BP readings differed by \(>5\) mm Hg, an additional measurement was required, and the mean value of three readings was used. Pulse pressure was calculated as SBP minus diastolic BP (DBP).

2 | METHODS

2.1 | Study participants

This is a community-based study conducted in the Liaobu County, Dongguan, Guangdong Province, China. The current study was approved by the Clinical Research Ethnic Committee of Guangdong Provincial People’s Hospital and the Liaobu County Health Department. Written informed consent was obtained before enrollment. During the government-sponsored annual health examination in 2016, 1474 hypertensive individuals underwent echocardiographic examination. In specific, the definition of hypertension was based on prior physician’s diagnosis and current antihypertensive therapy. Individuals who did not have data on tissue Doppler imaging (\(n = 464\), had prior ischemic stroke (\(n = 23\), and had coronary heart disease (\(n = 24\)) were excluded. Among these 47 individuals with prior CVD, 8 were also without data on tissue doppler imaging. Therefore, a total of 971 hypertensive individuals without CVD were included for the current analyses.

2.2 | Clinical characteristics and laboratory data

Clinical characteristics were collected using standardized questionnaire by trained healthcare staffs during the annual health examination. Body mass index (BMI) was calculated by weight in kilograms divided by height in squared meters, and BMI ≥28 kg/m\(^2\) was defined as obesity based on the World Health Organization criteria for the Asian population.\(^18\) Body surface area (BSA) was calculated as BSA = (Weight \(^{0.425}\) × Height \(^{0.725}\)) × 0.007184. Waist circumference was measured at the level of the midpoint between the top of the iliac crest and the lower margin of the last palpable rib in the midaxillary line, and hip circumference was measured at the level of the widest portion of buttocks. Waist-hip ratio was calculated as waist circumference divided by hip circumference. Fasting venous blood was used to assess fasting plasma glucose, lipid profiles, serum uric acid, and serum creatinine, which was used to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula,\(^19\) and eGFR <60 ml/min/1.73 m\(^2\) was defined as chronic kidney disease. Hyperuricemia was defined as serum uric acid ≥420 µmol/L in men and ≥360 µmol/L in women, respectively. Current antihypertensive and other drugs use were collected.

2.3 | Blood pressure measurement

Prior to BP measurement, participants were required to stay at rest in a sitting position for 5 minutes. According to the China guideline’s recommendation,\(^20\) two BP measurements were performed with 1-minute interval with the arm positioned at the heart level using Omron HEM-7051 device (Omron HealthCare). Healthcare staff was attended during BP measurements. The average value of two BP readings was used. If the first two BP readings differed by \(>5\) mm Hg, an additional measurement was required, and the mean value of three readings was used. Pulse pressure was calculated as SBP minus diastolic BP (DBP).

2.4 | Echocardiographic examination

Echocardiographic examination was performed according to the American Society of Echocardiography and the European Association of Cardiovascular Imaging guideline’s recommendation \(^21\) using a Vivid S6 M4S-RS Probe (GE Ving-Med) interfaced with a 2.5- to 3.5-MHz phased-array probe. Left atrial (LA) volume was assessed using the modified biplane Simpson’s rule from the apical 2- and 4-chamber view at end systole and was indexed to BSA. LV end-diastolic diameter (LVEDD), LV posterior wall and interventricular septum thickness in diastole were used to calculate left ventricular mass (LVM) and were indexed to BSA. LVM index ≥115 g/m\(^2\) in men and ≥95 g/m\(^2\) in women were defined as LV hypertrophy (LVH). Mitral inflow velocity (peak E- and A-wave) was assessed using pulsed-wave Doppler from the apical 4-chamber view. Peak early systolic tissue velocity (S’) and peak early diastolic tissue velocity (e’) were measured from the septal aspect of the mitral annulus.
According to the guideline recommendation, septal e’ velocity <7 cm/s was defined as LV diastolic dysfunction and septal E/e’ ratio >15 was defined as an increased LV filling pressure. Stroke volume (SV) was calculated as LV end-diastolic volume (LVEDV) minus LV end-systolic volume (LVESV) and was indexed to BSA. Based on prior report, effective arterial elastance (Ea) and Ees were calculated as Ea = 0.9 × SBP/SV and Ees = 0.9 × SBP/LVESV, and the Ea/Ees ratio was used to assess arterial-ventricular coupling. LV end-diastolic elastance (Eed) was calculated as Eed = (11.96 + 0.596 × E/e’) / LVEDV as previously validated.

2.5 | Statistical analysis

Continuous variables were presented as mean ± standard deviation if normal distribution, otherwise were presented as median and interquartile range (IQR). Between-group differences were evaluated by t test or Mann-Whitney U test. Categorical variables were presented as number and proportion. Between-group differences were evaluated by Chi-square test or the Fisher exact test. We first compared cardiac and arterial indices by sex, and then we used linear regression analyses to evaluate the association between age (per 10 years increase) with cardiac and arterial indices in men and women, respectively, and the association was tested for potential interaction by sex. Participants were separated into two achieved SBP levels based on the 2017 AHA/ACC hypertension guideline (<130 mm Hg vs. ≥130 mm Hg) and the 2018 China hypertension guideline (<140 mm Hg vs. ≥140 mm Hg). We evaluated age-related alterations in selected cardiac and arterial indices with interaction by sex according to the achieved SBP level. The association between age (per 10 years increase) with selected cardiac and arterial indices was evaluated in women and men, respectively, and the association was tested for interaction by sex. β-coefficient and associated 95% confidence interval (CI) were reported. A p-value <.05 was considered as statistical significance. All the analyses were performed using R package (version 3.4 Vienna).

3 | RESULTS

3.1 | Baseline characteristics

The mean age of the cohort was 66.5 years, and women accounted for 62% (n = 602) of the study participants (Table 1). Age distribution was shown in Figure 1. Compared to men, women were older, more likely to be obese and dyslipidemia, and less likely to smoke. Women had a lower DBP and waist/hip ratio but had a higher BMI. Women were less likely than men to use diuretic.

3.2 | Comparisons of cardiac and arterial structure and function by sex

Women had a worse cardiac remodeling as reflected by a higher LA volume index and were more likely than men to have LA volume index >34 ml/m², and concentric and eccentric LVH (Table 2). Although women had a higher LVEF and SV index, septal S’ velocity was lower in women. Women had a worse LV diastolic function as reflected by a lower septal e’ velocity, a higher septal E/e’ ratio, and were more likely than men to have septal e’ velocity <7 cm/s and septal E/e’ ratio >15. LV and arterial stiffness were greater in women as reflected by a higher Ees, Eed, Ea, and pulse pressure in women. Arterial-ventricular coupling was worse in women as they had a lower Ea/Ees ratio.

3.3 | Age-related alterations in indices of LV diastolic function in women and men

Left atrial volume index and septal E/e’ ratio incrementally increased and septal e’ velocity incrementally decreased across increasing age group, and these trends were observed in both sexes (Figure 2, Panel A-C). After adjusting for covariates, increasing age remained associated with these indices in both sexes (Table 3). In the interaction analyses, septal E/e’ ratio increased more steeply with age in women than in men (p-interaction = .001), while the association between age with LA volume index and septal e’ velocity did not differ by sex.

3.4 | Age-related alterations in indices of LV and arterial stiffness in women and men

End-systolic elastance and Eed incrementally increased across increasing age group only in women (Figure 2, Panel D-E). After adjusting for covariates, increasing age remained associated with Ees and Eed in women (Table 3). The analysis of interaction suggested that the association between age with Eed was greater in women than in men (p-interaction = .002). Both Ea and pulse pressure increased with age in women, and pulse pressure increased with age in men (Figure 2, Panel F-G). After adjusting for covariates, increasing age remained associated with Ea and pulse pressure in women, while associated with pulse pressure in men. The analysis of interaction suggested that the association between age with Ea was greater in women than in men (p-interaction = .005). There was no association between age with Ea/Ees ratio in both sexes.

3.5 | Age-related alterations in indices of LV structure and systolic function in women and men

Left ventricular mass index increased across increasing age group in women (Figure 2, Panel I). After adjusting for covariates, increasing age remained associated with LVM index in women (Table 3). There was no association between age with LV mass-to-volume (LVMV) ratio in both sexes. Septal S’ velocity incrementally decreased across increasing age group in both sexes. After adjusting for covariates, increasing age remained associated with septal S’ velocity in both sexes (Figure 2, Panel M and Table 3). The analysis of interaction
indicated that the association between age with septal $S'$ velocity was greater in women than in men ($p$-interaction = .048). The association between age with LVEF and SV index did not differ by sex.

3.6 | Age-related alterations in selected cardiac and arterial indices according to the achieved SBP level

Among individuals with the achieved SBP $\leq 130$ mm Hg, after adjusting for covariates, the magnitude of the association between age with septal $S'$ velocity, septal $E/e'$ ratio, $Ea$, and $Eed$ did not differ by sex (Table 4). Nonetheless, among individuals with the achieved SBP $> 130$ mm Hg, similar findings were observed as SBP $< 130$ mm Hg except that the magnitude of the association between age with septal $E/e'$ ratio was greater in women. Among individuals with the achieved SBP $\geq 140$ mm Hg, similar findings were observed as SBP $> 130$ mm Hg except that the magnitude of the association between age with septal $S'$ velocity did not differ by sex.

### TABLE 1 Baseline characteristics

| Variables | Overall ($n=971$) | Men ($n=369$) | Women ($n=602$) | $p$-Value |
|-----------|------------------|---------------|-----------------|-----------|
| Age (years) | 66.5 ± 11.4 | 64.2 ± 12.3 | 67.8 ± 10.7 | <.001 |
| SBP (mm Hg) | 137.0 ± 16.7 | 136.9 ± 15.8 | 137.1 ± 17.2 | .893 |
| DBP (mm Hg) | 81.9 ± 10.5 | 83.8 ± 10.7 | 80.8 ± 10.2 | <.001 |
| Heart rate (beat per minute) | 71.7 ± 12.0 | 72.0 ± 12.3 | 71.5 ± 11.8 | .572 |
| Smoking, n (%) | 208 (21.4) | 203 (55.0) | 5 (0.8) | <.001 |
| Physical inactivity, n (%) | 408 (42.0) | 148 (40.1) | 260 (43.2) | .38 |
| Body surface area (m²) | 1.62 ± 0.18 | 1.73 ± 0.15 | 1.55 ± 0.15 | <.001 |
| Body mass index (kg/m²) | 25.3 ± 3.8 | 24.9 ± 3.5 | 25.5 ± 3.9 | .024 |
| Obesity, n (%) | 205 (21.1) | 61 (16.5) | 144 (23.9) | .008 |
| Waist/hip ratio | 0.93 ± 0.06 | 0.94 ± 0.05 | 0.92 ± 0.06 | <.001 |
| Dyslipidemia, n (%) | 597 (75.6) | 209 (71.1) | 388 (78.2) | .03 |
| Diabetes mellitus, n (%) | 216 (22.3) | 75 (20.3) | 141 (23.5) | .283 |
| Hypertension, n (%) | 614 (64.7) | 244 (67.4) | 370 (63.0) | .194 |
| CKD, n (%) | 124 (13.3) | 50 (14.0) | 74 (12.8) | .684 |
| FPG (mmol/L) | 5.4 ± 1.5 | 5.3 ± 1.6 | 5.4 ± 1.5 | .379 |
| Total cholesterol (mg/dl) | 211.1 ± 53.5 | 200.1 ± 49.6 | 217.9 ± 54.7 | <.001 |
| LDL cholesterol (mg/dl) | 129.1 ± 38.4 | 125.3 ± 37.2 | 131.6 ± 39.0 | .072 |
| HDL cholesterol (mg/dl) | 53.5 ± 14.4 | 50.2 ± 16.1 | 55.7 ± 12.7 | <.001 |
| Triglyceride (mg/dl) | 132.6 [96.2, 190.7] | 128.5 [93.6, 190.1] | 135.0 [97.5, 193.2] | .994 |
| Creatinine (µmol/L) | 79.3 ± 35.1 | 94.7 ± 46.0 | 69.7 ± 21.2 | <.001 |
| eGFR (ml/min/1.73 m²) | 83.5 ± 24.0 | 82.4 ± 23.8 | 84.2 ± 24.1 | .27 |
| Uric acid (µmol/L) | 429.2 ± 124.2 | 471.4 ± 121.9 | 403.2 ± 118.3 | <.001 |
| Aspirin, n (%) | 167 (17.2) | 73 (19.8) | 94 (15.6) | .113 |
| Statins, n (%) | 272 (28.0) | 112 (30.4) | 160 (26.6) | .231 |
| Oral antidiabetics, n (%) | 175 (18.0) | 64 (17.3) | 111 (18.4) | .73 |
| Insulin, n (%) | 4 (0.4) | 3 (0.8) | 1 (0.2) | .312 |
| Allopurinol, n (%) | 22 (2.3) | 12 (3.3) | 10 (1.7) | .163 |
| ACEI, n (%) | 144 (14.8) | 62 (16.8) | 82 (13.6) | .207 |
| ARB, n (%) | 489 (50.4) | 187 (50.7) | 302 (50.2) | .929 |
| CCB, n (%) | 454 (46.8) | 166 (45.0) | 288 (47.8) | .424 |
| Diuretic, n (%) | 137 (14.1) | 63 (17.1) | 74 (12.3) | .047 |
| Betablocker, n (%) | 127 (13.1) | 48 (13.0) | 79 (13.1) | 1 |
| No. antihypertensive drugs | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | .302 |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.

*Presented as median [Q1, Q3].
4 | DISCUSSION

This community-based study, which included 971 hypertensive individuals without CVD, shows that women had worse LV diastolic function and greater LV and arterial stiffness. Increasing age was associated with worse LV diastolic function and greater LV and arterial stiffness in women. Importantly, the sex differences in the association between age with selected cardiac and arterial indices varied according to the achieved SBP level. Since age and sex are non-modifiable, achieving SBP target, especially at a lower level (<130 mm Hg), might be beneficial to attenuate the sex differences in age-related alterations in cardiac and arterial structure and function.

4.1 | Association between age with LV diastolic function

Several indices from different pathophysiological aspects (eg, LV relaxation and LV stiffness) have been used to characterize LV diastolic function. Septal e’ velocity, septal E/e’ ratio, and LA volume index are used commonly in clinical practices and researches. Age is an important determinant of LV diastolic function, and several studies have assessed the association between age with LV diastolic function. For example, in individuals without CVD and hypertension, increasing age was associated with incremental impairment of LV diastolic function in both sexes. We confirm prior studies by demonstrating that in hypertensive individuals without CVD, LV diastolic function, as indexed by septal e’ velocity, septal E/e’ ratio and LA volume index, incrementally reduced with increasing age in both women and men. Considering a higher burden of HfPEF in elderly women, it is of clinical importance to explore whether the magnitude of the associations between age with LV diastolic function differs by sex. We extend prior studies by showing that increasing age was associated with greater increase in septal E/e’ ratio and Eed (an index of LV diastolic stiffness) in women than in men. Mechanistically, LV stiffening causes impairment of LV diastolic function, resulting in elevation of LV filling pressure, which explain why age was associated with a higher septal E/e’ ratio in women than in men.

Results from Okura showed that in individuals younger than 50 years, e’ velocity was higher in women; while in those between 50 and 70 years, e’ velocity was similar between women and men; and in individuals older than 70 years, e’ velocity was lower in women. We observe that in individuals younger than 55 years, septal e’ velocity was higher in women, while in those older than 55 years, septal e’ velocity was lower in women. Lack of cardioprotective effects of estrogen after menopause might contribute to impairment of LV relaxation in elderly women. Indeed, prior studies have demonstrated that estrogen replacement therapy was beneficial for improvement of LV diastolic function.

Left atrial volume index is an essential marker of long-term LV diastolic function. Using cardiac magnetic resonance, Zemrak and colleagues reported that age and female sex were positively associated with LA volume index. Using echocardiography, D’Andrea and colleagues reported that in healthy individuals, LA volume index was correlated to age but not sex. Consistent to prior reports, the current study demonstrates that age was positively associated with LA volume index. However, the magnitude of the association did not differ by sex. Taken together, the overall findings suggest that in hypertensive individuals without CVD, increasing age is associated with greater increases in LV filling pressure and LV stiffness in women, providing mechanistic evidence to explain the predisposition of elderly women to have HfPEF.

4.2 | Association between age with arterial and LV stiffness

Arterial stiffening is implicated in LV diastolic dysfunction and HfPEF development. Age is a key determinant of arterial stiffness. Elderly women usually have a greater arterial stiffness than elderly men. We confirm prior studies by showing that increasing age was associated with increase in pulse pressure, and pulse pressure was higher in women than in men after
65 years. We additionally assessed the association between age with Ea, which is a reliable marker of arterial stiffness that captures peripheral vascular resistance, pulsatile load, and systolic and diastolic time intervals.\textsuperscript{39,40} The current study suggests that age was associated with Ea only in women, and the magnitude of the association was greater in women. Elevated vascular oxidative stress and inflammation after menopause might contribute to a steep increase in arterial stiffness in elderly women.\textsuperscript{38,41} Indeed, in the current study, we observe that both Ea and pulse pressure increased significantly after 55 years in women. Improvement of arterial stiffness with estrogen replacement therapy also supports this hypothesis.\textsuperscript{42,43

| Variables                                      | Overall (n = 971) | Men (n = 369) | Women (n = 602) | p-Value |
|------------------------------------------------|------------------|--------------|-----------------|---------|
| Left atrial volume (ml)                        | 42.8 ± 21.0      | 42.7 ± 22.5  | 42.9 ± 20.0     | .885    |
| Left atrial volume index (ml/m\textsuperscript{2}) | 26.5 ± 13.2      | 24.7 ± 13.4  | 27.6 ± 13.0     | .001    |
| Left atrial volume index >34 ml/m\textsuperscript{2}, n (%) | 180 (18.5)       | 50 (13.6)    | 130 (21.6)      | .004    |
| Interventricular septum thickness (mm)         | 9.7 ± 1.3        | 10.0 ± 1.3   | 9.5 ± 1.3       | <.001   |
| Posterior wall thickness (mm)                  | 9.5 ± 1.8        | 9.8 ± 1.9    | 9.3 ± 1.8       | <.001   |
| Relative wall thickness                        | 0.43 ± 0.09      | 0.43 ± 0.09  | 0.43 ± 0.08     | .245    |
| Relative wall thickness >0.42, n (%)           | 493 (50.8)       | 197 (53.4)   | 296 (49.2)      | .226    |
| LVEDD (mm)                                     | 44.7 ± 4.4       | 45.8 ± 4.6   | 44.1 ± 4.1      | <.001   |
| LVESD (mm)                                     | 27.5 ± 4.2       | 28.6 ± 4.5   | 26.9 ± 3.8      | <.001   |
| LVEDV (ml)                                     | 92.4 ± 22.0      | 97.9 ± 24.0  | 89.1 ± 19.9     | <.001   |
| LVEDV index (ml/m\textsuperscript{2})          | 57.1 ± 12.6      | 56.5 ± 13.0  | 57.5 ± 12.3     | <.001   |
| LVESV (ml)                                     | 29.4 ± 12.4      | 32.4 ± 14.5  | 27.6 ± 10.4     | <.001   |
| LVESV index (ml/m\textsuperscript{2})          | 18.1 ± 7.3       | 18.7 ± 8.1   | 17.8 ± 6.8      | .067    |
| Left ventricular mass (g)                      | 146.2 ± 42.1     | 159.0 ± 45.5 | 138.4 ± 37.9    | <.001   |
| Left ventricular mass index (g/m\textsuperscript{2}) | 90.1 ± 12.8     | 91.7 ± 25.0  | 89.1 ± 23.0     | .105    |
| Left ventricular hypertrophy, n (%)            | 242 (24.9)       | 53 (14.4)    | 189 (31.4)      | <.001   |
| LVMV ratio (g/ml)                              | 1.59 ± 0.32      | 1.64 ± 0.33  | 1.57 ± 0.32     | .001    |
| Left ventricular geometry                      | 375 (38.6)       | 150 (40.7)   | 225 (37.4)      | .342    |
| Normal, n (%)                                  | 354 (36.5)       | 166 (45.0)   | 188 (31.2)      | <.001   |
| Concentric remodeling, n (%)                  | 103 (10.6)       | 22 (6.0)     | 81 (13.5)       | <.001   |
| Concentric hypertrophy, n (%)                 | 139 (14.3)       | 31 (8.4)     | 108 (17.9)      | <.001   |
| Eccentric hypertrophy, n (%)                  | 32 (3.3)         | 9 (2.5)      | 23 (3.8)        | .458    |
| Septal S’ velocity (cm/s)                     | 6.4 ± 1.5        | 6.8 ± 1.4    | 6.2 ± 1.6       | <.001   |
| Left ventricular ejection fraction (%)         | 67.6 ± 7.1       | 66.7 ± 7.0   | 68.2 ± 7.0      | .001    |
| Stroke volume (ml)                             | 65.0 ± 14.9      | 68.0 ± 15.9  | 63.1 ± 13.9     | <.001   |
| Stroke volume index (ml/m\textsuperscript{2}) | 40.3 ± 8.5       | 39.4 ± 8.4   | 41.0 ± 8.5      | .041    |
| Peak E-wave velocity (m/s)                    | 0.68 ± 0.21      | 0.67 ± 0.21  | 0.69 ± 0.21     | .05     |
| Peak A-wave velocity (m/s)                    | 0.87 ± 0.19      | 0.82 ± 0.20  | 0.90 ± 0.18     | <.001   |
| E/A ratio                                      | 0.80 ± 0.25      | 0.85 ± 0.30  | 0.77 ± 0.22     | <.001   |
| Septal e’ velocity (cm/s)                     | 5.5 ± 1.8        | 5.9 ± 1.8    | 5.2 ± 1.7       | <.001   |
| Septal e’ velocity <7 cm/s, n (%)             | 728 (75.0)       | 239 (64.8)   | 489 (81.2)      | <.001   |
| Septal E/e’ ratio                              | 13.4 ± 5.4       | 12.0 ± 5.3   | 14.3 ± 5.2      | <.001   |
| Septal E/e’ ratio >15, n (%)                  | 273 (28.1)       | 57 (15.4)    | 216 (35.9)      | <.001   |
| Ees (mm Hg/ml)                                 | 4.74 ± 1.80      | 4.35 ± 1.88  | 4.98 ± 1.71     | <.001   |
| Eed (mm Hg/ml)                                 | 0.23 ± 0.06      | 0.21 ± 0.06  | 0.24 ± 0.06     | <.001   |
| Ea (mm Hg/ml)                                  | 1.99 ± 0.52      | 1.93 ± 0.52  | 2.03 ± 0.52     | .03     |
| Ea/Ees ratio                                   | 0.47 ± 0.17      | 0.50 ± 0.19  | 0.45 ± 0.15     | <.001   |
| Pulse pressure (mm Hg)                         | 55.2 ± 14.4      | 53.2 ± 14.0  | 56.4 ± 14.5     | .001    |

Abbreviations: Ea, effective arterial elastance; Eed, left ventricular end-diastolic elastance; Ees, left ventricular end-systolic elastance; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; LVMV, left ventricular mass-to-volume.
End-systolic elastance is an index of LV systolic stiffness. Prior study reported that age was associated with Ees in both sexes, and the magnitude of the association was greater in women.\(^7\) In the current study, age was associated with Ees only in women and the magnitude of the association did not differ by sex. Differences in the findings are not surprising given that multiple determinants (eg, age and arterial load) might influence Ees. Ees normally matches with arterial load to achieve near optimal mechanical and metabolic function.\(^{44}\) Therefore, an increase in Ees with age is served as a corresponding alteration to match with Ea increase with age. Notwithstanding, higher Ea and Ees indicate that arterial and LV stiffness become more sensitive to LV volume alteration, resulting in abnormalities of LV diastolic filling.\(^{45}\) The important role of arterial-ventricular coupling in the pathophysiology of LV diastolic dysfunction and HFpEF has long been recognized.\(^{46}\) Ea/Ees ratio is an index of arterial-ventricular coupling, and maximal cardiac efficiency is achieved when Ea/Ees ratio equals 0.5.\(^{47}\) In the current study, women had a lower mean Ea/Ees ratio than men (0.45 mm Hg/ml vs. 0.50 mm Hg/ml), suggesting a lower cardiac efficiency and worse cardiac performance. These findings together provide additional mechanistic evidence to explain the HFpEF epidemic in the elderly women.

**FIGURE 2** Alterations in cardiac and arterial structure and function across increasing age groups in women and men. Across increasing age groups, there was a trend of increase in LA volume index (Panel A), septal E/e’ ratio (Panel C) and pulse pressure (Panel G) and a trend of decrease in septal e’ velocity (Panel B) and septal S’ velocity (Panel M) in women and men. There was a trend of increase in Ees (Panel E), Eed (Panel D), Ea (Panel F), and LVM index (Panel I) with increasing age only in women, and no significant trend of alterations in Ea/Ees (Panel H), LVMV ratio (Panel J), LVEF (Panel K), and SV index (Panel L) with increasing age in both sexes. Blue line indicates men and red line indicates women. Ea, effective arterial elastance; Eed, left ventricular end-diastolic elastance; Ees, left ventricular end-systolic elastance; LA, left atrial; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMV, left ventricular mass-to-volume; SV, stroke volume.
4.3 | Association between age with LV structure and systolic function

Among community populations without CVD, findings regarding the association between age with LVM index are inconsistent. Cheng and colleagues reported that increasing age was associated with a reduction in LVM index in both sexes,8 which was opposite to the findings from the other study.7 Results from Japanese populations suggested no significant association between age with LVM index in both sexes.6 Interestingly, in the current study, age was positively associated with LVM index in women only. LVM index has multiple determinants and differences in the determinants such as ethnicity, age, clinical characteristics, and measurements might explain these differences. In individuals without CVD, age was associated with increase in LVEF and decrease in SV index.8 The other study reported a poor correlation between age with LVEF and S′ velocity.4 In the current study, only significant association between age with septal S′ velocity was observed, and the association was greater in women than in men. Septal S′ velocity measures longitudinal LV contraction and is a surrogate of clinical LV systolic function. Results of the current study suggest that in hypertensive individuals without CVD, despite with a normal range of LVEF, a greater reduction of septal S′ velocity with age in women further supports that women had a lower cardiac efficiency and worse cardiac performance.

4.4 | Achieving SBP target attenuates the sex differences in age-related alterations in selected cardiac and arterial indices

Novel to this study is our observation that achieving a lower SBP target (<130 mm Hg vs. <140 mm Hg) might be more helpful to attenuate the sex differences in age-related alterations in selected
FIGURE 2 (Continued)
cardiac and arterial indices. Indeed, when the achieved SBP <130 mm Hg, the magnitude of the associations between age with septal S’ velocity, septal E/e’ ratio, Ea, and Eed did not differ by sex. Similar but less consistent findings were also observed when SBP <140 mm Hg. Solomon and colleagues reported that in uncontrolled hypertensive individuals with LV diastolic dysfunction, a lower achieved SBP level was associated with a better achieved LV diastolic relaxation.16 Li and colleagues 14 recently reported that cardiac and vascular responses to BP elevation were greater in women than in men. Considering the non-modifiable nature of age, achieving a lower SBP target might be more beneficial to improve age-related alterations in cardiac and arterial structure and function in women.

4.5 Limitations

There are some limitations of the current study, first, the cross-sectional nature of the data, which limits conclusions about causality. Second, although we discussed possible relationship between estrogen and arterial and LV stiffness, the exact menstrual status as well as estrogen concentration of the study participants is unknown. Third, the current study only measured septal e′ velocity and the findings might not be generalized to the e′ velocity obtained from lateral mitral annulus. Fourth, the mean age of participants in the study approached 65 years and the findings might not be generalized to the young populations. Fifth, although statistical differences were observed in several parameters according to age by sex (eg, septal e’ velocity), considering the relatively small sample size, the

| TABLE 3 Association between age with indices of cardiac and arterial structure and function |
|-----------------------------------------|------------------------------------------|-----------------|-----------------|-----------------|
| Per 10 years increase in age            | β-coefficient (95% confidence interval)  | Men             | Women           | p-Interaction   |
| Left atrial volume index (ml/m²)        | 1.53 (−0.34, 3.40)                       | 0.97 (−0.55, 2.48) | .637            |
| Septal e’ velocity (cm/s)               | −0.55 (−0.68, −0.41)                     | −0.74 (−0.85, −0.63) | .029            |
| Septal E/e’ ratio                       | 0.36 (−0.08, 0.80)                       | 1.39 (1.01, 1.77)  | <.001           |
| Left ventricular mass index (g/m²)      | 1.64 (−0.44, 3.71)                       | 2.04 (0.31, 3.76)  | .768            |
| LVMV ratio (g/ml)                       | 0.004 (−0.020, 0.028)                    | 0.004 (−0.024, 0.031) | .988            |
| LVEF (%)                                | 0.06 (−0.53, 0.64)                       | −0.31 (−0.84, 0.22) | .36             |
| SV index (ml/m²)                        | 0.60 (−0.37, 1.57)                       | −0.01 (−0.91, 0.89) | .364            |
| Septal S’ (m/s)                         | −0.30 (−0.42, −0.19)                     | −0.47 (−0.58, −0.36) | .038            |
| Ees (mm Hg/ml)                          | 0.06 (−0.10, 0.21)                       | 0.24 (0.11, 0.36)  | .071            |
| Eed (mm Hg/ml)                          | 0.006 (0.001, 0.010)                     | 0.016 (0.01, 0.020) | .004            |
| Ea (mm Hg/ml)                           | 0.04 (−0.02, 0.10)                       | 0.13 (0.07, 0.18)  | .038            |
| Ea/Ees ratio                            | 0.010 (−0.012, 0.032)                    | 0.001 (−0.014, 0.017) | .501            |
| Pulse pressure (mm Hg)                  | 3.10 (1.98, 4.23)                        | 3.91 (2.87, 4.95)  | .303            |

Per 10 years increase in age

| Adjusted β-coefficient (95% confidence interval) |
|-----------------------------------------|------------------------------------------|-----------------|-----------------|
| Left atrial volume index (ml/m²)        | 3.29 (1.02, 5.57)                        | 2.30 (0.61, 4.00) | .358            |
| Septal e’ velocity (cm/s)               | −0.64 (−0.80, −0.49)                     | −0.74 (−0.87, −0.61) | .115            |
| Septal E/e’ ratio                       | 0.66 (0.14, 1.18)                        | 1.45 (1.00, 1.89)  | .001            |
| Left ventricular mass index (g/m²)      | 1.61 (−0.91, 4.13)                       | 2.14 (0.13, 4.14)  | .805            |
| LVMV ratio (g/ml)                       | 0.004 (−0.023, 0.032)                    | 0.007 (−0.026, 0.040) | .603            |
| LVEF (%)                                | −0.26 (−0.99, 0.47)                      | −0.39 (−1.02, 0.24) | .225            |
| SV index (ml/m²)                        | 0.27 (−0.95, 1.49)                       | −0.15 (−1.22, 0.92) | .219            |
| Septal S’ (m/s)                         | −0.27 (−0.41, −0.13)                     | −0.45 (−0.58, −0.32) | .048            |
| Ees (mm Hg/ml)                          | −0.02 (−0.22, 0.17)                      | 0.18 (0.04, 0.33)  | .064            |
| Eed (mm Hg/ml)                          | 0.006 (0.001, 0.012)                     | 0.014 (0.009, 0.019) | .002            |
| Ea (mm Hg/ml)                           | 0.03 (−0.04, 0.11)                       | 0.12 (0.06, 0.18)  | .005            |
| Ea/Ees ratio                            | 0.020 (−0.010, 0.040)                    | 0.002 (−0.020, 0.020) | .634            |
| Pulse pressure (mm Hg)                  | 3.23 (1.85, 4.62)                        | 4.06 (2.83, 5.30)  | .274            |

Note: Adjusting for smoking, body mass index, waist/hip ratio, diabetes mellitus, eGFR, uric acid and antihypertensive drugs.

Abbreviations: Ea, effective arterial elastance; Eed, left ventricular end-diastolic elastance; Ees, left ventricular end-systolic elastance; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMV, left ventricular mass-to-volume; SV, stroke volume.
clinical implications of these differences were unclear and deserve further investigation. Last but not the least, no sex difference in the selected parameters among the subgroup of SBP <130 mm Hg might be partly due to the lack of statistical power. However, the current study provided preliminary findings based on which future studies can investigate whether achieving a lower SBP level can mitigate the sex differences in cardiac and vascular remodeling.

5 | CONCLUSION

In conclusion, results of the current study provide additional mechanical evidence to explain the predisposition of elderly women to have HFrEF. The novelty of the current study is that achieving SBP target, especially at a lower level, might be more beneficial to mitigate the age-related alterations in cardiac and arterial structure and function in women.

ACKNOWLEDGEMENTS

We thank the participants and all health staffs in Liaobu County for assistance with data collection.

CONFLICT OF INTEREST

The authors disclose that they do not have conflict of interest.

AUTHOR CONTRIBUTIONS

Anping Cai wrote the paper; Dan Zhou performed echocardiogram examination; Lin Liu conducted statistical analysis; Yingling Zhou helped conduct the current study; Songtao Tang and Yingqing Feng conceived, designed, and conducted this cohort study.

ORCID

Anping Cai https://orcid.org/0000-0003-3953-5881

REFERENCES

1. Zacharias M, Joffe S, Konadu E, et al. Clinical epidemiology of heart failure with preserved ejection fraction (HFrEF) in comparatively young hospitalized patients. Int J Cardiol. 2016;202:918-921.
2. Tromp J, Teng TH, Tay WT, et al. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019;21(1):23-36.
3. Tromp J, Shen L, Jhund PS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74(5):601-612.
4. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction in older adults. Heart Fail Clin. 2017;13(3):485-502.
5. Li H, Hastings MH, Rhee J, Trager LE, Roh JD, Rosenzweig A. Targeting age-related pathways in heart failure. Circ Res. 2020;126(4):533-551.
6. Okura H, Takada Y, Yamabe A, et al. Age- and gender-specific changes in the left ventricular relaxation: a Doppler echocardiographic study in healthy individuals. Circ Cardiovasc Imaging. 2009;2(1):41-46.
7. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. *Circulation*. 2005;112(15):2254-2262.

8. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging*. 2009;2(3):191-198.

9. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. *Circ. Res.* 2019;124(11):1598-1617.

10. Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. *Front Physiol*. 2019;10:638.

11. Kosmala W, Marwick TH. Asymptomatic left ventricular diastolic dysfunction: predicting progression to symptomatic heart failure. *JACC Cardiovasc Imaging*. 2020;13(1 Pt 2):215-227.

12. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*. 2017;14(10):591-602.

13. Tibrewala A, Yancy CW. Heart failure with preserved ejection fraction in women. *Heart Fail Clin*. 2019;15(1):9-18.

14. Li Z, Liu J, Shen J, et al. Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases. *Postgrad Med*. 2020;133(2):181-187.

15. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. *Lancet*. 2007;369(9579):2079-2087.

16. Solomon SD, Verma A, Desai A, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *Hypertension*. 2010;55(2):241-248.

17. Merz AA, Cheng S. Sex differences in cardiovascular ageing. *Heart (British Cardiac Society)*. 2016;102(11):825-831.

18. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363(9403):157-163.

19. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med*. 2006;145(4):247-254.

20. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. *J Geriatr Cardiol*. 2019;16(3):182-241.

21. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39.e14.

22. Nagaeff SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.

23. Beale AL, Nanayakkara S, Segan L, et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed invasive hemodynamic and echocardiographic analysis. *JACC Heart Fail*. 2019;7(3):239-249.

24. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. *Circulation*. 2000;102(15):1788-1794.

25. Borlaug BA, Redfield MM, Melenovsky V, et al. Longitudinal changes in left ventricular stiffness: a community-based study. *Circ Heart Fail*. 2013;6(5):944-952.

26. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACPMA/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6):e13-e115.

27. Nagaeff SF. Left ventricular diastolic function: understanding pathophysiology, diagnosis, and prognosis with echocardiography. *JACC Cardiovasc Imaging*. 2020;13(1 Pt 2):228-244.

28. Zhao Z, Wang H, Jessup JA, Lindsey SH, Chappell MC, Groban L. Role of estrogen in diastolic dysfunction. *Am J Physiol Heart Circ Physiol*. 2014;306(5):H628-640.

29. Maslov PZ, Kim JK, Argulian E, et al. Is cardiac diastolic dysfunction a part of post-menopausal syndrome? *JACC Heart Fail*. 2019;7(3):192-203.

30. Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. *J Am Coll Cardiol*. 2000;36(2):529-533.

31. Yildirir A, Yarali H, Kabakci G, Aybar F, Akgul E, Bukulmez O. Hormone replacement therapy to improve left ventricular diastolic functions in healthy postmenopausal women. *Int J Gynaecol Obstet*. 2001;75(3):273-278.

32. Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73(15):1961-1977.

33. Zemrak F, Ambale-Venkatesh B, Captur G, et al. Left atrial structure and function in relationship to age, sex, ethnicity, and cardiovascular risk factors: MESA (Multi-Ethnic Study of Atherosclerosis). *Circ Cardiovasc Imaging*. 2017;10(2):e005379.

34. D’Andrea A, Riegler L, Rucco MA, et al. Left atrial volume index in healthy subjects: clinical and echocardiographic correlates. *Echocardiography*. 2013;30(9):1001-1007.

35. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. *Eur Heart J*. 2018;39(30):2780-2792.

36. Sun Z. Aging, arterial stiffness, and hypertension. *Hypertension*. 2015;65(2):252-256.

37. Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. *Circulation*. 2018;138(2):198-205.

38. DuPont JJ, Kenney RM, Patel AR, Jaffe IZ. Sex differences in mechanisms of arterial stiffness. *Br J Pharmacol*. 2019;176(21):4208-4225.

39. Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. *Circulation*. 1992;86(2):513-521.

40. Chemla D, Antony I, Lecarpentier Y, Nitenberg A. Contribution of systemic vascular resistance and total arterial compliance to effective arterial elastance in humans. *Am J Physiol Heart Circ Physiol*. 2003;285(2):H614-620.

41. Hildreth KL, Kohrt WM, Moreau KL. Oxidative stress contributes to large elastic arterial stiffening across the stages of the menopausal transition. *Menopause*. 2014;21(6):624-632.

42. Rajkumar C, Kingwell BA, Cameron JD, et al. Hormonal therapy increases arterial compliance in postmenopausal women. *J Am Coll Cardiol*. 1997;30(2):350-356.

43. Yoshizawa M, Maeda S, Miyaki A, et al. Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. *Am J Physiol Heart Circ Physiol*. 2009;297(5):H1899-H1903.

44. Chantler PD, Lakatta EG. Arterial-ventricular coupling with aging: implications for dysfunctional aging. *Front Physiol*. 2012;3:90.

45. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age:
implications for pressure regulation and cardiac reserve in the elderly. *J Am Coll Cardiol*. 1998;32(5):1221-1227.

46. Ikonomidis I, Aboyans V, Blacher J, et al. The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases. European Association of Cardiovascular Imaging, and Heart Failure Association. *Eur J Heart Fail*. 2019;21(4):402-424.

47. Chirinos JA. Ventricular-arterial coupling: invasive and non-invasive assessment. *Artery Res*. 2013;7(1):2.